MBX Biosciences, Inc. Common Stock·Healthcare
Immune Therapeutics (OTCMKTS:IMUN - Get Free Report) and MBX Biosciences (NASDAQ: MBX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Earnings and Valuation This table compares Immune
CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the issuance of an equity inducement award to Karen Basbaum in connection with her commencement of employment as the company's new Chief Business Officer.
The president & CEO of MBX Biosciences reported the acquisition of 18,500 indirectly held shares for about $526,000 on March 13, 2026. The indirect holdings (486,777 shares) are maintained via the P.
Shares of MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company. The average
Microbix Biosystems Inc. (MBX:CA) Shareholder/Analyst Call Transcript
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted recent corporate progress.
